CKD-MBD Tied to Malnutrition-Inflammation Complex Syndrome
A new review highlights the need to simultaneously control CKD-MBD and MICS in patients receiving hemodialysis.
Secondary Hyperparathyroidism
Therapies to Slow Vascular Calcification in CKD Explored
Promising therapies still need to be further evaluated in clinical trials.
Etelcalcetide vs Cinacalcet Treatment Adherence Examined
Secondary hyperparathyroidism remains uncontrolled in many patients with chronic kidney disease.
Earlier Calcimimetic Use May Allow Better PTH Control in Hemodialysis
Recent studies have shown the importance of starting treatment at lower phosphorus and PTH levels on long-term outcomes of SHPT.
Parathyroidectomy Increasing in the United States
Despite the increasing availability of calcimimetics, parathyroidectomy rates in the US have gradually increased.
Post-Parathyroidectomy Hypocalcemia Risk Factors Identified
Patients at risk for postoperative hypocalcemia need more vigilant postoperative monitoring.
Alendronate Protects Against Bone Loss in Kidney Transplant Recipients
Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation.
Electrolyte Abnormalities Common in Solid Organ Transplant Recipients
Hypercalcemia was common among kidney transplant recipients at 3 months, investigators reported.
CKD-MBD Marker Changes Vary Across Dialysis Modalities
Use of home dialysis and modalities other than conventional in-center hemodialysis is expected to grow.
Etelcalcetide Effective in Cases Where Cinacalcet Is Problematic
Switching from oral to intravenous calcimimetic may lower PTH levels in patients on hemodialysis with poor tolerance.
- Loading...
Loading...
Next post in Secondary Hyperparathyroidism
Loading... 
Loading...